Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
March 2020
in “
Cns & Neurological Disorders-drug Targets
”
Studysummary In this study, researchers analyzed lurasidone's risk profile for treating schizophrenia and bipolar depression, identifying unlisted adverse reactions like hypersexuality, restless leg syndrome, thrombocytopenia, and telogen effluvium, which show probable or possible correlations with the drug.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on eurekaselect.com →